A Phase 2/3 Trial to Evaluate ANA001 for the Treatment of Moderate to Severe COVID-19
Latest Information Update: 03 Jun 2021
At a glance
- Drugs Niclosamide (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors NeuroBo Pharmaceuticals
- 03 Jun 2021 New trial record